Advancing New Healthcare Solutions Through Collaboration

Consumer - Medical Devices - Pharmaceuticals - Global Public Health

We are proud to share that our single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.

Building on those results, the data also suggest that humoral and cellular immune responses lasted through at least 8 months, the latest timepoint recorded in the study thus far.

08 July 2021

Black Innovators QFC_Award Announncement_Twitter

EADAM named Awardee in Black Innovators in Skin Health QuickFire Challenge

Johnson & Johnson Innovation, together with Neutrogena®, recently announced that EADEM has been selected as the awardee in Black Innovators in Skin Health QuickFire Challenge. The challenge offered an opportunity for U.S.-based Black innovators working on potential skin and scalp health solutions to receive grant funding and mentorship.

22 July 2021

How many of us were wondering what would happen in 2021 – the “post-Covid era”?

Hear from Dan Wang, Head of Johnson & Johnson Innovation in APAC who sees that while there are challenges there is a future of rising opportunities.

08 July 2021

Our COVID-19 Response

Johnson & Johnson Innovation is committed to helping patients, our partners and communities around the world manage the unprecedented impact of COVID-19.

17 December 2020